Peer reviewed, NIH-funded R01 Bayesian study from the VHA demonstrates direct correlation between reduced HAIs and EPA Registered EOScu.
NORFOLK, VA, UNITED STATES, May 7, 2026 /EINPresswire.com/ — EOS Surfaces, LLC today announced the publication of a new peer-reviewed study demonstrating a direct correlation between the use of EOScu biocidal surfaces and meaningful reductions in healthcare-associated infections (HAIs). The study, NIH-funded R01 research with public relevancy, has been conducted over more than a decade and represents one of the most comprehensive evaluations to date of a continuously active surface intervention in real-world, clinical environments.
Leveraging advanced statistical modeling techniques, researchers analyzed longitudinal data across multiple care settings to isolate the impact of EOScu on infection rates. The findings show a clear and sustained association between the installation of EOScu surfaces and reductions in preventable HAIs, even when accounting for other infection control measures, seasonality, diagnosis, staffing, and other potential confounders.
“This study reflects the level of rigor and duration that is often missing in evaluations of infection prevention technologies,” said Ken Tinder, CEO of EOS Surfaces. “We are encouraged to see proof that EOScu can prevent life-threatening infections as well as reduce healthcare costs.”
The research was conducted as part of a National Institutes of Health (NIH) R01-funded project, underscoring both the scientific credibility of the work and the importance of exploring scalable, evidence-based approaches to reducing infection risk in healthcare environments.
“Our study is unique in both its duration and rigor. Ten years of longitudinal data, combined with advanced statistical modeling, provides a level of evidence we rarely see in infection prevention research. The consistency of the findings over time gives us confidence that this is not a short-term effect, but a sustained and meaningful reduction in healthcare-associated infections due to the novel biocidal surface,” said Dr. Chetan Jinadatha, lead investigator on the study.
Healthcare-associated infections remain a persistent and costly challenge for hospitals and care facilities across the United States. In addition to their impact on patient outcomes, HAIs carry significant financial implications, particularly as reimbursement models continue to penalize preventable adverse events.
The study’s findings suggest that the reduction in infection rates associated with EOScu surfaces may offset the initial investment required for installation. By continuously reducing microbial burden on high-touch surfaces, EOScu provides a passive, always-on layer of protection that complements existing infection prevention protocols.
EOScu is currently being installed in Department of Veterans Affairs (VA) healthcare facilities nationwide, reflecting growing recognition of the need for durable, infrastructure-based solutions to infection control.
“This is not a short-term intervention or a behavior-dependent solution,” added Trinder. “EOScu is a way to approach the gold standard in healthcare: Zero harm.”
EOScu preventive, biocidal surfaces are the only synthetic surfaces EPA-registered for public health claims and have been in active use in healthcare environments for over a decade. The material is impregnated with safe, non-resistance-forming copper oxide throughout the entire matrix, delivering continuous biocidal activity without additional human intervention. The full study is available in the American Journal of Infection Control.
About EOS Surfaces, LLC | EOS Surfaces, LLC is a medical materials developer and manufacturer in Norfolk, VA specializing in EPA-registered self-sanitizing surfaces. The company has developed novel and proprietary processes for embedding biocidal cuprous oxide into a polymer matrix, creating self-sanitizing and biocidal surfaces for use in hospitals and healthcare facilities as part of their infection prevention protocol. Compatible with all infection prevention processes on the market (including chemical and UV), EOScu is the only practical intervention that is continuously self-sanitizing without requiring additional human intervention and training. Published, peer-reviewed clinical trials show statistically significant reductions in actual incidents of healthcare associated infection and maintained as well as overall lower mean bioburden beyond 24 hours. The company also developed Health. Care. | An Educational Blog that serves as a unique and valuable resource for patients, physicians and the hospital C-suite. For more info, visit http://eoscu.com/.
Media Contact
EOS Surfaces LLC
+17574788730 ext.
mediacontact@eos-surfaces.com
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
